UFPT Quote, Financials, Valuation and Earnings

Repligen has a net margin of 11.37% compared to UFP Technologies's net margin of -20.22%. UFP Technologies's return on equity of 18.87% beat Repligen's return on equity of -1.29%.

UFP Technologies has a consensus price target of $381.00, signalling upside risk potential of 80.75%. On the other hand Repligen has an analysts' consensus of $190.47 which suggests that it could grow by 45.48%. Given that UFP Technologies has higher upside potential than Repligen, analysts believe UFP Technologies is more attractive than Repligen.

UFP Technologies has a beta of 1.079, which suggesting that the stock is 7.904% more volatile than S&P 500. In comparison Repligen has a beta of 1.266, suggesting its more volatile than the S&P 500 by 26.606%.

UFP Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Repligen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. UFP Technologies pays -- of its earnings as a dividend. Repligen pays out -- of its earnings as a dividend.

UFP Technologies quarterly revenues are $144.1M, which are smaller than Repligen quarterly revenues of $167.5M. UFP Technologies's net income of $16.4M is higher than Repligen's net income of -$33.9M. Notably, UFP Technologies's price-to-earnings ratio is 27.74x while Repligen's PE ratio is 633.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UFP Technologies is 3.25x versus 11.61x for Repligen. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of 11.37% compared to UFP Technologies's net margin of -1226.82%. UFP Technologies's return on equity of 18.87% beat VolitionRX's return on equity of --.

UFP Technologies has a consensus price target of $381.00, signalling upside risk potential of 80.75%. On the other hand VolitionRX has an analysts' consensus of $3.37 which suggests that it could grow by 523.88%. Given that VolitionRX has higher upside potential than UFP Technologies, analysts believe VolitionRX is more attractive than UFP Technologies.

UFP Technologies has a beta of 1.079, which suggesting that the stock is 7.904% more volatile than S&P 500. In comparison VolitionRX has a beta of 1.155, suggesting its more volatile than the S&P 500 by 15.463%.

UFP Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. UFP Technologies pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

UFP Technologies quarterly revenues are $144.1M, which are larger than VolitionRX quarterly revenues of $474.5K. UFP Technologies's net income of $16.4M is higher than VolitionRX's net income of -$5.8M. Notably, UFP Technologies's price-to-earnings ratio is 27.74x while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UFP Technologies is 3.25x versus 34.90x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

West Pharmaceutical Services has a net margin of 11.37% compared to UFP Technologies's net margin of 17.38%. UFP Technologies's return on equity of 18.87% beat West Pharmaceutical Services's return on equity of 18.15%.

UFP Technologies has a consensus price target of $381.00, signalling upside risk potential of 80.75%. On the other hand West Pharmaceutical Services has an analysts' consensus of $285.01 which suggests that it could grow by 28.67%. Given that UFP Technologies has higher upside potential than West Pharmaceutical Services, analysts believe UFP Technologies is more attractive than West Pharmaceutical Services.

UFP Technologies has a beta of 1.079, which suggesting that the stock is 7.904% more volatile than S&P 500. In comparison West Pharmaceutical Services has a beta of 1.221, suggesting its more volatile than the S&P 500 by 22.112%.

UFP Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. West Pharmaceutical Services offers a yield of 0.37% to investors and pays a quarterly dividend of $0.21 per share. UFP Technologies pays -- of its earnings as a dividend. West Pharmaceutical Services pays out 12% of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

UFP Technologies quarterly revenues are $144.1M, which are smaller than West Pharmaceutical Services quarterly revenues of $748.8M. UFP Technologies's net income of $16.4M is lower than West Pharmaceutical Services's net income of $130.1M. Notably, UFP Technologies's price-to-earnings ratio is 27.74x while West Pharmaceutical Services's PE ratio is 33.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UFP Technologies is 3.25x versus 5.64x for West Pharmaceutical Services. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of 11.37% compared to UFP Technologies's net margin of -10.04%. UFP Technologies's return on equity of 18.87% beat Xtant Medical Holdings's return on equity of -35.34%.

UFP Technologies has a consensus price target of $381.00, signalling upside risk potential of 80.75%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 272.34%. Given that Xtant Medical Holdings has higher upside potential than UFP Technologies, analysts believe Xtant Medical Holdings is more attractive than UFP Technologies.

UFP Technologies has a beta of 1.079, which suggesting that the stock is 7.904% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.033, suggesting its less volatile than the S&P 500 by 103.341%.

UFP Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. UFP Technologies pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

UFP Technologies quarterly revenues are $144.1M, which are larger than Xtant Medical Holdings quarterly revenues of $31.5M. UFP Technologies's net income of $16.4M is higher than Xtant Medical Holdings's net income of -$3.2M. Notably, UFP Technologies's price-to-earnings ratio is 27.74x while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UFP Technologies is 3.25x versus 0.54x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.